EFFECTS OF BETA-BLOCKING AGENT METIPRANOLOL ON METABOLIC VARIABLES IN PATIENTS WITH ISCHEMIC HEART-DISEASE, HYPERKINETIC SYNDROME, HYPERTHYREOSIS AND IN HEALTHY-SUBJECTS

  • 1 January 1979
    • journal article
    • research article
    • Vol. 17  (6) , 244-249
Abstract
Metabolic effects of metipranolol, a new beta adrenergic blocking agent, were studied in patients with ischemic heart disease, hyperkinetic syndrome, hyperthyroidism and in healthy subjects. Administration of the drug (30 mg/day for 1 wk) resulted in the decrease of noradrenaline [norepinephrine] excretion, blood free fatty acid level and in lowering of blood pressure and heart rate, particularly in patients with ischemic heart disease and hyperkinetic syndrome. These alterations were accompanied by alleviation of clinical symptoms. Metipranolol by suppressing the activity of sympathetic nervous system and thereby diminishing lipolysis, apparently exerts favorable clinical effects, most probably related to diminution of myocardial O2 consumption.

This publication has 3 references indexed in Scilit: